找回密码
 To register

QQ登录

只需一步,快速开始

扫一扫,访问微社区

Titlebook: Endocrine Therapy of Breast Cancer; Current Developments Franco Cavalli Book 1987Latest edition Springer-Verlag Berlin Heidelberg 1987 brea

[复制链接]
楼主: 脾气好
发表于 2025-3-25 05:28:16 | 显示全部楼层
Book 1987Latest edition discussed. It was decided to keep the layout very simple in order to keep costs to a minimum and make the monographs available in the shortest possible time, thus overcoming a common problem in medical literature: that of the material being outdated even before publication. Umberto Veronesi Chairma
发表于 2025-3-25 08:28:59 | 显示全部楼层
发表于 2025-3-25 14:46:50 | 显示全部楼层
Book 1987Latest editionorientated courses, by promoting new educational initiatives. One of these is the cloister seminars, short meetings intended for highly qualified oncologists and dealing with specific, controversial aspects of clinical practice and research. Another is the institution of permanent study groups, also
发表于 2025-3-25 17:26:24 | 显示全部楼层
发表于 2025-3-25 23:28:37 | 显示全部楼层
发表于 2025-3-26 02:19:05 | 显示全部楼层
Introduction,eting, held in spring 1987 in Venice, on the new premises of the European School of Oncology. I think that the quality of this second volume is even better and I am therefore confident of its success.
发表于 2025-3-26 05:53:58 | 显示全部楼层
Values and Limitations of Current Criteria for Objective Response in Advanced Breast Cancer,te and duration of response. In phase II trials response rate can be used only to estimate the antitumor activity of a specific therapy, whereas in phase III trials it is used as a measure of efficacy based on the expectation that a high rate of response will be translated into a benefit in terms of prolonged time to progression and/or survival.
发表于 2025-3-26 11:24:09 | 显示全部楼层
Representing Uncertain Knowledgeon of this plateau induces a critical re-evaluation of the overall approach to this disease. This paper will focus mainly on one methodological aspect which is generally underestimated in most reviews.
发表于 2025-3-26 13:42:05 | 显示全部楼层
发表于 2025-3-26 17:42:39 | 显示全部楼层
https://doi.org/10.1057/9780230504370te and duration of response. In phase II trials response rate can be used only to estimate the antitumor activity of a specific therapy, whereas in phase III trials it is used as a measure of efficacy based on the expectation that a high rate of response will be translated into a benefit in terms of prolonged time to progression and/or survival.
 关于派博传思  派博传思旗下网站  友情链接
派博传思介绍 公司地理位置 论文服务流程 影响因子官网 SITEMAP 大讲堂 北京大学 Oxford Uni. Harvard Uni.
发展历史沿革 期刊点评 投稿经验总结 SCIENCEGARD IMPACTFACTOR 派博系数 清华大学 Yale Uni. Stanford Uni.
|Archiver|手机版|小黑屋| 派博传思国际 ( 京公网安备110108008328) GMT+8, 2025-6-9 00:36
Copyright © 2001-2015 派博传思   京公网安备110108008328 版权所有 All rights reserved
快速回复 返回顶部 返回列表